SY-5007 Clinical Trials

1 actively recruiting trial

No change since May 2026

Also known as: SY-5007 tablets

Pipeline

Phase 3: 1

Top Sponsors

Shouyao Holdings (Beijing) Co. LTD1

Indications

Lung Cancer1
Non Small Cell Lung Cancer1
Cancer1

Other1 trial

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.